Evidence map›Paper›PMID 40622369›Full record

ArticleAnnals of medicine2025

Yougui pills prevent ovariectomy-induced bone loss by suppressing Th17 response and IL-17/NF-κB pathway.

Peng Zhang, Luting Lin, Ningrui Wang, Ying Wang, Yuqi Miao, Jun Fei, Qimiao Hu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Peng ZhangDepartment of Orthopedics, Hangzhou Red Cross Hospital, Hangzhou, China.
Luting LinThe Third Clinical College, Zhejiang Chinese Medical University, Hangzhou, China.
Ningrui WangThe Third Clinical College, Zhejiang Chinese Medical University, Hangzhou, China.
Ying WangDepartment of Orthopedics, Hangzhou Red Cross Hospital, Hangzhou, China.
Yuqi MiaoThe Third Clinical College, Zhejiang Chinese Medical University, Hangzhou, China.
Jun FeiDepartment of Orthopedics, Hangzhou Red Cross Hospital, Hangzhou, China.
Qimiao HuThe Third Clinical College, Zhejiang Chinese Medical University, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOsteoporosis is a chronic metabolic bone disease that causes excessive osteoclast formation, ultimately resulting in massive bone loss. Yougui pills (YGPs) are the classic traditional Chinese medicine formula with an anti-osteoporosis effect, but the underlying mechanisms are unknown. MATERIALS AND

methodsThe ameliorative impact of YGPs on bone loss in ovarectomized mice model was examined by Alcian Blue Haematoxylin (ABH) staining and micro-CT scanning. The "YGPs-osteoporosis-target" network was established and analyzed to explore the molecular mechanism of YGPs on osteoporosis. In addition, flow cytometry and immunohistochemistry (IHC) were used to detect the Th17 response and the expression levels of CD4, IL-17A, RANKL, and RORγt. Finally, we examined the expressions of p-P65, nuclear factor of activated T cells 1 (NFATc1), and cathepsin K (CTSK) by IHC and immunofluorescence (IF) staining to investigate the inhibitory effects of YGPs on osteoclast formation and function

resultsThe results of ABH staining and micro-CT scanning showed that YGPs can significantly prevent bone loss. The 'YGPs-osteoporosis-target' network found that IL-17 is the key target, and its effects may be closely related to the upstream Th17 cells and the downstream NF-κB pathway of IL-17. Meanwhile, Th17 response and the expression levels of CD4, IL-17A, RANKL, and RORγt increased in the OVX group compared with the sham group, while YGPs treatment significantly reduced the above conditions. We also found that the number and function of osteoclasts (OCs) were significantly increased by incubation with IL-17, while YGPs treatment inhibited osteoclast formation and function. Furthermore, YGPs can suppress the expression of p-P65, NFATc1, and CTSK by IHC and IF staining

conclusionYGPs can exert anti-osteoporosis effects by regulating osteoimmunity, and the mechanism is to inhibit osteoclast formation and bone loss by suppressing the Th17 response and IL-17/NF-κB pathway.

Indexed as

Bone ResorptionDrugs, Chinese HerbalOsteoporosisTh17 CellsAnimalsCathepsin KDisease Models, AnimalFemaleInterleukin-17MiceMice, Inbred C57BLNFATC Transcription FactorsNF-kappa BNuclear Receptor Subfamily 1, Group F, Member 3OsteoclastsOvariectomyCathepsin KDrugs, Chinese HerbalIl17a protein, mouseInterleukin-17NFATC Transcription FactorsNF-kappa BNuclear Receptor Subfamily 1, Group F, Member 3RANK Ligandbone lossNF-κBovariectomyTh17YGPs

Identifiers

PMID40622369
PMCPMC12239122

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.